You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ID: GL-END 3-25 nov 2023
Type of Content: Guidelines & Advice, Advice Report
Document Status: Current
Authors:
K. Zukotynski, C. Arinze, G. Kulkarni, S. Hotte, A. Loblaw, Genitourinary Disease Site Group

Objective

The objectives of this guideline are to provide guidance for the most contemporary management for men with metastatic castration-resistant prostate cancer (mCRPC) and optimize treatment.

Patient Population

Patients with prostate cancer who are eligible for treatment with 177Lutetium-prostate-specific membrane antigen-617 (177Lutetium-PSMA-617).

Intended Guideline Users

This guideline is targeted for clinicians involved in the care of patients with prostate cancer who are eligible for treatment with 177Lutetium-PSMA-617.

pdf download Full Report (PDF) (399.09 Ko)